

GenSight Biologics Announces the Filing of its 2024 Universal Registration Document

Paris, France, April 8, 2024, 7:00 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the filing on April 7, 2025 of its 2024 Universal Registration Document (URD) in English with the French market authority (*Autorités des Marchés Financiers*, or AMF).

The Universal Registration Document includes in particular:

- The 2024 annual financial report;
- The management report;
- The report on corporate governance; and
- The description of the share buyback program.

The Universal Registration Document may be consulted on the Company's website (www.gensight-biologics.com), "Investors" section, and on the AMF's website (www.amf-france.org).

Contacts

GenSight Biologics

Chief Financial Officer

Jan Eryk Umiastowski

jeumiastowski@gensight-biologics.com

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolpharovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.